ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

ClinicalTrials.gov ID: NCT05020236

Public ClinicalTrials.gov record NCT05020236. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 10, 2026, 8:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR

Study identification

NCT ID
NCT05020236
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
944 participants

Conditions and interventions

Interventions

  • Daratumumab Drug
  • Dexamethasone Drug
  • Elranatamab Drug
  • Pomalidomide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 3, 2021
Primary completion
Apr 26, 2026
Completion
May 30, 2027
Last update posted
May 4, 2026

2021 โ€“ 2027

United States locations

U.S. sites
11
U.S. states
4
U.S. cities
10
Facility City State ZIP Site status
Clovis Community Medical Center Clovis California 93611 Active, not recruiting
Community Regional Medical Center Fresno California 93721 Active, not recruiting
UCHealth Poudre Valley Hospital Fort Collins Colorado 80524 Active, not recruiting
UCHealth Greeley Hospital Greeley Colorado 80634 Active, not recruiting
Sylvester Comprehensive Cancer Center - Aventura Aventura Florida 33180 Recruiting
Sylvester Comprehensive Cancer Center - Coral Springs Coral Springs Florida 33065 Recruiting
University of Miami Hospital and Clinics - Deerfield Beach Deerfield Beach Florida 33442 Recruiting
Sylvester Comprehensive Cancer Center - Hollywood Hollywood Florida 33021 Recruiting
University of Miami Hospital and Clinics Miami Florida 33136 Recruiting
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). New York New York 10021 Recruiting
Memorial Sloan Kettering Cancer Center - Main Campus New York New York 10065 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 79 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05020236, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 4, 2026 ยท Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05020236 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record โ†’